Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: LYEL

Lyell Immunopharma, Inc.

Healthcare | Biotechnology

Market prices for LYEL are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-12.65

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:41 UTC.

What Lyell Immunopharma, Inc. does

Lyell Therapeutics is a clinical-stage cell therapy company developing autologous chimeric antigen receptor T-cell products to treat cancer. The company's lead program, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CAR T-cell therapy designed to improve outcomes in large B-cell lymphoma by targeting B cells through two pathways and generating more durable immune cells. Ronde-cel is being evaluated in two clinical trials: a pivotal single-arm study in heavily pretreated patients and a Phase 3 head-to-head randomized trial against approved CAR T therapies.

Summarized from Lyell Immunopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-12.65

Revenue, margins & earnings

FY2021: net loss $250M on revenue $11M$11MFY2021FY2022: net loss $183M on revenue $85M$85MFY2022FY2023: net loss $235M on revenue $130,000$130,000FY2023FY2024: net loss $343M on revenue $61,000$61,000FY2024FY2025: net loss $274M on revenue $36,000$36,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-13
  • 2026-10-13Chief Medical OfficerSale-422$3.6K
  • 2026-09-10Chief Medical OfficerSale-500$6.3K
  • 2026-09-10Chief Medical OfficerOption (right to buy)Award47,500—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Lyell Immunopharma, Inc. do?

Lyell Therapeutics is a clinical-stage cell therapy company developing autologous chimeric antigen receptor T-cell products to treat cancer.

When did LYEL last file with the SEC?

Lyell Immunopharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-09-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:41 UTC. This page is also available as JSON at /api/data?ticker=LYEL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LYEL and 5,000+ tickers.

Create a free account — keep LYEL
For your agent
GET /api/data?ticker=LYEL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt